- Home
- DYNX vs ABEO Comparison
DYNX vs ABEO Comparison
Compare DYNX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYNX
- ABEO
- Stock Information
- Founded
- DYNX 2024
- ABEO N/A
- Country
- DYNX United States
- ABEO United States
- Employees
- DYNX N/A
- ABEO N/A
- Industry
- DYNX
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- DYNX
- ABEO Health Care
- Exchange
- DYNX NYSE
- ABEO Nasdaq
- Market Cap
- DYNX 220.4M
- ABEO 253.0M
- IPO Year
- DYNX 2024
- ABEO 1980
- Fundamental
- Price
- DYNX $9.86
- ABEO $5.78
- Analyst Decision
- DYNX
- ABEO Strong Buy
- Analyst Count
- DYNX 0
- ABEO 4
- Target Price
- DYNX N/A
- ABEO $17.25
- AVG Volume (30 Days)
- DYNX 4.4K
- ABEO 271.9K
- Earning Date
- DYNX 01-01-0001
- ABEO 03-17-2025
- Dividend Yield
- DYNX N/A
- ABEO N/A
- EPS Growth
- DYNX N/A
- ABEO N/A
- EPS
- DYNX N/A
- ABEO N/A
- Revenue
- DYNX $2,124,981.00
- ABEO N/A
- Revenue This Year
- DYNX N/A
- ABEO N/A
- Revenue Next Year
- DYNX N/A
- ABEO $15,721.96
- P/E Ratio
- DYNX N/A
- ABEO N/A
- Revenue Growth
- DYNX N/A
- ABEO 147.52
- 52 Week Low
- DYNX $9.91
- ABEO $3.05
- 52 Week High
- DYNX $10.00
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- DYNX N/A
- ABEO 52.03
- Support Level
- DYNX N/A
- ABEO $5.79
- Resistance Level
- DYNX N/A
- ABEO $6.16
- Average True Range (ATR)
- DYNX 0.00
- ABEO 0.23
- MACD
- DYNX 0.00
- ABEO 0.02
- Stochastic Oscillator
- DYNX 0.00
- ABEO 50.00
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.